Sanofi ends option phase of rare disease p...Sanofi and Alnylam have agreed to end the research and option phase of the companies’ RNAi therapeutics alliance in rare genetic diseases. more ➔
Medigene AG in potential €1bn licence an...Roivant Sciences and Sinovant Sciences have launched newco Cytovant Sciences, which licenced two T cell-based cancer immune therapies and two development programmes from Medigene AG for commercialisation … more ➔
AMR diagnostic specialist Gradientech rais...Gradientech closes a USD 4.6 million rights issue to progress QuickMIC diagnostic system for ultra-rapid antibiotics susceptibility testing (AST). more ➔
123rf.com/Iculig AgomAb Therapeutics bags €21m Series A f...AgomAb Therapeutics, a company resulting from a collaboration of argenx SE and growth factor experts from the University of Turin, has completed a €21m Series A financing. more ➔
Novartis acquires inflammasome blocker com...Novartis has aquired all outstanding capital stock and paid US$310m upfront to Boston-based IFM Tre Inc., which commercialises three inflammasome blockers designed to treat chronic inflammatory dise … more ➔
EMA recommends bluebird’s ?-thalasse...The European Medicines Agency has granted conditional approval for bluebird bio NV’s gene therapy Zynteglo (LentiGlobin BB305) to treat the rare disease transfusion-dependent ?-thalassemia at its … more ➔
Selvita to spin out cancer businessKrakow-based Selvita S.A. has announced it will spin out its oncology unit this year resulting in two public companies, a CRO and a cancer therapeutics developer. more ➔
Polyneuron Pharma raise CHF22.5m in Series...The CHF22.5m Series A financing round of the Swiss specialist for autoimmune diseases was led by Sofinnova Partners and New Enterprise Associates together with contributions of existing investors. more ➔
Genfit prices IPO at $135mFrench liver disorder specialist Genfit SA has announced the pricing of its Nasdaq IPO of ADS and European private placement. more ➔
Evotec partners with Mark Foundation for C... Evotec AG and The Mark Foundation for Cancer Research have inked a R&D collaboration aimed at developing novel immunooncological drugs more ➔
123rf.com/Iculig
